TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05106920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NMP
Description: Participants received the percutaneous electrical stimulation intervention. Specifically, this consisted of the application of a square wave biphasic electrical current, to cause a tolerable muscle contraction. The application was 10 stimulations of 10 seconds, with 10 seconds at rest between stimulations. A trained physiotherapist performed the PNM intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NMP
Description: Participants received the percutaneous electrical stimulation intervention. Specifically, this consisted of the application of a square wave biphasic electrical current, to cause a tolerable muscle contraction. The application was 10 stimulations of 10 seconds, with 10 seconds at rest between stimulations. A trained physiotherapist performed the PNM intervention.
Study: NCT04688398

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Seal oil
Description: Consumption of seal oil once per day (at breakfast)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Consumption of vegetable oil once per day (at breakfast)
Study: NCT05818319

Intervention type: OTHER
Group type: OTHER
Intervention: 12 hours ETI pause
Description: Patients with CF are randomly allocated to ETI pause lasting 12 hours.

Intervention type: OTHER
Group type: OTHER
Intervention: 36 hours ETI pause
Description: Patients with CF are randomly allocated to ETI pause lasting either 36 hours.

Intervention type: OTHER
Group type: OTHER
Intervention: 60 hours ETI pause
Description: Patients with CF are randomly allocated to ETI pause lasting either 60 hours.
Study: NCT05168072

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: m-Health app
Description: M-Health app is used to set weight loss targets and record body weights online. Participants learn the calories they consumed by using the m-Health APP and follow the APP for physical exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional outpatient obesity management
Description: Diet and exercise guidance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional outpatient obesity management
Description: Diet and exercise guidance
Study: NCT05805007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZVS203e
Description: ZVS203e is a rAAV-mediated gene editing drug that silences RHO mutant protein expression by CRISPR/Cas9 editing system.
Study: NCT06065228

Intervention type: OTHER
Intervention: AlgometRx Nociometer
Description: Physiologic characterization of disease activity

Intervention type: OTHER
Intervention: AlgometRx Nociometer
Description: Physiologic characterization of disease activity
Study: NCT05821465

Intervention type: DEVICE
Intervention: HeartWatch
Description: The HeartWatch monitoring device will be worn on the upper left arm for the same duration or up to 48 hours that the standard event recorder or holter monitor is worn. The subject will be provided with a HelpWear smartphone that is paired to the monitor and only used by the participant to tag any events that they may have during the Heartwatch monitoring session.

Intervention type: DEVICE
Intervention: HeartWatch
Description: The HeartWatch monitoring device will be worn on the upper left arm for the same duration or up to 48 hours that the standard event recorder or holter monitor is worn. The subject will be provided with a HelpWear smartphone that is paired to the monitor and only used by the participant to tag any events that they may have during the Heartwatch monitoring session.
Study: NCT06084247

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Curved KARL STORZ fetoscope
Description: The KARLZ STORZ curved scope is used to see the inside of a pregnant person's uterus during minimally invasive surgery, similar to conventional scopes. The curved scope is rounded and thought to help visualize the anterior placenta because of its position on the uterus.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Scopes
Description: The conventional scopes are regularly used during laser photocoagulation of placental anastomoses.
Study: NCT05918861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalcetrapib
Description: Cholesterol Ester Transfer Protein Inhibitor, 300 mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo tablets
Study: NCT06482333

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time for resumption of DOAC
Description: Time for resumption of DOAC

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Time for resumption of DOAC
Description: Time for resumption of DOAC
Study: NCT06319872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral disulfiram
Description: 250 mg/day
Study: NCT05289687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab / Hyaluronidase Injection
Description: Daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 1, 8, 15, and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab / Hyaluronidase Injection
Description: Patients that are MRD Negative on Day 29 will receive daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 36, 43, 50, and 57.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab / Hyaluronidase Injection
Description: Patients that remain MRD positive on Day 29 will receive a combination of daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 36, 43, 50, and 57 and chemotherapy selected from the combinations listed below:~* Cytarabine 3000 mg/m2, IV, Every 12 hours for 4 doses on Days 37 and 38~* Methotrexate 1000 mg/m2, IV, Over 24 hours on Day 36~OR~* Methotrexate, Starting dose 100 mg/m2, IV, Days 36, 46, 56~* Vincristine, 1.5 mg/m2 (2 mg cap), IV, Days 36, 46, 56~* Pegaspargase, 2000 IU/m2 (Capped at 3750 IU), IV Days 37, 57~* Methotrexate 15 mg, IT, Days 36, 56

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab / Hyaluronidase Injection
Description: All patients with MRD negative response after completion of previous course are eligible for daratumumab-hyaluronidase 1800mg/ 30,000 units every 2 weeks on Days 1,15, 29, 43, 57, 71, 85, and 99 for 8 doses.
Study: NCT06235697

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: 46Gy / 23 fractions of EBRT to pelvis and prostate + LDR or HDR boost to prostate~+ Adjuvant ADT: Unfavourable Intermediate Risk: 6 months or High / Very High Risk: 24 months

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation SBRT only
Description: 25Gy / 5 fractions to pelvis + 40 Gy / 5 fractions to prostate (SBRT)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADT
Description: Assigned at enrollment
Study: NCT05830669

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Description: 3 cycles of 5 min inflation of a blood-pressure cuff to 200 millimetres of mercury (mmHG) (or at least to a pressure 50 mmHG higher than the systolic arterial pressure) to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham RIPC
Description: 3 cycles of 5 min inflation of a blood-pressure cuff to 20 mmHG to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed
Study: NCT05958108

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SinergiAPS intervention
Description: Audit and feedback intervention, with the audit being based on patient-reported experiences and outcomes of patient safety.
Study: NCT04212143

Intervention type: OTHER
Intervention: there is no intervention
Description: There is no intervention in this study. It is observational only.

Intervention type: OTHER
Intervention: there is no intervention
Description: There is no intervention in this study. It is observational only.
Study: NCT05962515

Intervention type: PROCEDURE
Intervention: ultrasound guided dry needling
Description: Dry needling was applied in the intervention room with sterile conditions the patient in the prone position.The low frequency (2-5 MHz) transducer is placed in the gluteal region in a slightly oblique position and sonographic scanning is started. First, the large mountain shadow of the iliac crest and gluteus maximus muscle is sonographically visualized in the midline. Then the transducer is shifted inferiorly until the sciatic notch is visualized. When the sciatic notch, sciatic nerve and the pear-shaped piriformis muscle above it are visualized, the patient's knee is flexed and the leg is rotated internally and externally, and the typical sliding motion of the piriformis muscle is observed. After the target point is determined, a 22 G spinal needle is applied from lateral to medial or from medial to lateral with in plane technique. The needle is inserted and withdrawn several times until the switch response in the piriformis muscle is observed and extinguished

Intervention type: PROCEDURE
Intervention: ultrasound guided dry needling
Description: Dry needling was applied in the intervention room with sterile conditions the patient in the prone position.The low frequency (2-5 MHz) transducer is placed in the gluteal region in a slightly oblique position and sonographic scanning is started. First, the large mountain shadow of the iliac crest and gluteus maximus muscle is sonographically visualized in the midline. Then the transducer is shifted inferiorly until the sciatic notch is visualized. When the sciatic notch, sciatic nerve and the pear-shaped piriformis muscle above it are visualized, the patient's knee is flexed and the leg is rotated internally and externally, and the typical sliding motion of the piriformis muscle is observed. After the target point is determined, a 22 G spinal needle is applied from lateral to medial or from medial to lateral with in plane technique. The needle is inserted and withdrawn several times until the switch response in the piriformis muscle is observed and extinguished
Study: NCT05648513

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interwiev
Description: Parent Attitudes About Childhood Vaccines Survey (PACV) will be implemented to the patients consulting to Atatürk City Hospital. Subjects with vaccine hesitancy will be randomly distributed to groups, and in this way, experimental (n=26) and control (n=26) groups will be formed. Routine antenatal monitoring will be kept with the control group. With the experimental group, on the other hand, motivational interviewing method will be implemented for 4 sessions of about 45 minutes each. Interviews will be held at 4 separate weekends, 1 session for each. Interviews will be performed via online means or face to face.
Study: NCT06425445

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Measurement of maximal expiratory pressures during forced static expiratory maneuvers sustained over 5 seconds
Description: Participants perform forced static expiratory maneuvers sustained over a five second period

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Measurement of maximal expiratory pressures during forced static expiratory maneuvers sustained over 5 seconds
Description: Participants perform forced static expiratory maneuvers sustained over a five second period
Study: NCT04701489

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Splenic ultrasound
Description: GE LOGIQ E10 device with C1-6 ultrasound probe
Study: NCT05658952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microcatheter-derived FFR
Description: FFR pullback trace is obtained through the manual retrieval performed after the positioning of the microcatheter FFR in the distal portion of the vessel. The pullback speed should be steady and the overall duration would be between 20 and 40 seconds. Then, the Interventional Cardiologist has to decide the procedural plan according to the pullback trace aiming to obtain an optimal post-PCI result in terms of physiology. FFR with pullback can be repeated after stenting to check and correct the result if needed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Angiography-derived FFR
Description: FFR pullback trace is automatically obtained after the 3-Dimensional reconstruction of the vessel through angiography derived FFR. Then, Interventional Cardiologist has to decide the procedural plan according to the pullback result aiming to obtain an optimal post-PCI result in terms of physiology. Angiography-derived FFR can be repeated after stenting to check and correct the result if needed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Angiography-guided PCI
Description: Interventional Cardiologist will perform PCI plan according to his/her the evaluation of angiography.
Study: NCT04698174

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transepithelial Photorefractive keratectomy (tPRK) without laser polishing
Description: Transepithelial Photorefractive keratectomy (tPRK) with laser ablation of the corneal epithelium and stroma in a single-step procedure using the B+L Teneo 317 Model 2 Excimer Laser.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transepithelial Photorefractive keratectomy (tPRK) with laser polishing
Description: Transepithelial Photorefractive keratectomy (tPRK) using the B+L Teneo 317 Model 2 Excimer Laser with end-treatment laser polishing using a fixed thickness of the additional layer of 5 μm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Photorefractive keratectomy (PRK)
Description: Conventional Photorefractive keratectomy (PRK) with alcohol-assisted epithelium ablation. Then the aspheric ablation profile will be performed using the B+L Teneo 317 Model 2 Excimer Laser.
Study: NCT05380102

Intervention type: DEVICE
Intervention: Telemetry monitoring
Description: All participants will be on standard telemetry monitoring for Heart Rate, Respiration Rate and movements using the gold standard (Electrocardiography and Capnography respectively).
Study: NCT04544943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioLexa- Cohort 1
Description: Twice daily application of topical BioLexa™ lotion, administered for 14 days in adult healthy subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioLexa- Cohort 1
Description: Twice daily application of topical BioLexa™ lotion, administered for 14 days in adult healthy subjects

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BioLexa- Cohort 2
Description: Twice daily application of topical BioLexa™ lotion, administered for 14 days in adult mild to moderate AD patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Twice daily (BID) application of placebo for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily (BID) application of placebo for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin
Description: Twice daily (BID) application of Gentamicin for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gentamicin
Description: Twice daily (BID) application of Gentamicin for 14 days
Study: NCT05380102

Intervention type: DEVICE
Intervention: Continuous monitoring through Earlysense
Description: EarlySense (USFDA approved ballistocardiography device) will be placed under the patients mattress to measure Heart Rate, Respiratory Rate and movements

Intervention type: DEVICE
Intervention: Continuous monitoring through Dozee VS
Description: Dozee VS will be placed under the patients mattress to measure Heart Rate, Respiratory Rate and movements
Study: NCT05489640

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention will be administered in this study.
Study: NCT06419010

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery with the use of L-PRF
Description: The study protocol is the same as the standard surgery one but with additional use of L-PRF membranes

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard surgery
Description: The standard surgical treatment, taking place in the operating room under general anesthesia
Study: NCT06344325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fospropofol
Description: The initial dose of fospropofol disodium in the youth group is 15mg/kg,the middle-aged group is 10mg/kg, the elderly group is 7.5mg/kg, and the concentration of adjacent intervals is 0.5mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fospropofol
Description: The initial dose of fospropofol disodium in the youth group is 15mg/kg,the middle-aged group is 10mg/kg, the elderly group is 7.5mg/kg, and the concentration of adjacent intervals is 0.5mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fospropofol
Description: The initial dose of fospropofol disodium in the youth group is 15mg/kg,the middle-aged group is 10mg/kg, the elderly group is 7.5mg/kg, and the concentration of adjacent intervals is 0.5mg/kg.
Study: NCT05903313

Intervention type: DRUG
Intervention: Chang Gung ECG Abnormality Detection Software
Description: This device is expected to be used for the static 12-lead ECG to detect whether there are abnormal ECG signals related to diseases and outputs the results.
Study: NCT05917808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ready-to-eat wholegrain porridge
Description: A ready-to-eat wholegrain porridget will be consumed shortly after a diagnostic OGTT on two consecutive evenings, the OGTT will then be repeated
Study: NCT01319175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip flexion strength training
Study: NCT06038006

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sleep Respiratory Monitoring System
Description: Millimeter-Wave radar-based Sleep Respiratory Monitoring System to be used on each participant undergoing PSG
Study: NCT04461184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Wellness Intervention for Aging
Description: Internet technologies have emerged as a platform for performing wellness interventions that also have wide outreach. Previous studies that have used the internet for delivering health interventions have found that older adults valued this platform, used it for researching health information and social communications. Likewise, the effectiveness of delivering health-related information intended for behavior change through the internet is equal to that of print-based delivery, thereby lowering costs and expanding reach. Thus, the internet provides a unique platform for conducting interventions. The internet based wellness intervention will be a low cost method focused on older adults to help increase intrinsic motivation through autonomy, competence, and relatedness (Intrinsic Motivation) to help increase daily physical activity.
Study: NCT04676633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: Investigational Product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: Investigational Product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: Investigational Product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: Investigational Product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: Investigational Product
Study: NCT06320327

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cannabidiol cream
Description: Group 1 will be administered the recommended quantity of CBD cream to be applied at various times throughout the study and used in a specific way instructed by the researcher (the cream is applied via massage through a standardized application method).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: Group 2 will be administered the recommended quantity of placebo cream to be applied at various times throughout the study and used in a specific way instructed by the researcher (the cream is applied via massage through a standardized application method).
Study: NCT05592236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic compression garments
Description: Dynamic compression garments for 2 hours a day in addition to standard therapy twice a week (1 session of 45 minutes) for a total of 6 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Standard therapy twice a week (1 session of 45 minutes) for a total of 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard therapy
Description: Standard therapy twice a week (1 session of 45 minutes) for a total of 6 weeks
Study: NCT06454318

Intervention type: DIAGNOSTIC_TEST
Intervention: Wellue O2 ring
Description: Wellue O2 ring wore when doing the polysomnography
Study: NCT06379698

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: personalized 3D model pré-opérative education
Description: Before surgery, during a preoperative therapeutic education consultation, a personalized 3D models will be presented to the patients according to the allocated study group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: generic 3D model pré-opérative education
Description: Before surgery, during a preoperative therapeutic education consultation, a generic 3D models will be presented to the patients according to the allocated study group
Study: NCT05282641

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10 g of collagen hydrolysate
Description: Before breakfast, participants consume 1 sachet every day for 4 weeks. The sachet contains 10-gram collagen protein hydrolysates + 5-gram erythritol and it has to be dissolved in 250 ml of water.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Before breakfast, participants consume 1 sachet every day for 4 weeks. The sachet contains 5-gram erythritol (placebo) and has to be dissolved in 250 ml of water.
Study: NCT05185297

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recreational Futsal
Description: Participants will participate in 2-3 weekly one hour sessions of Recreational Futsal, during 3 months, while maintaining standard care provided by the family physician.
Study: NCT04745377

Intervention type: DIAGNOSTIC_TEST
Intervention: IgG neutralising antibody titers to S1 and S2 proteins of SARS-COV-2 virus
Description: IgG neutralising antibody titers to S1 and S2 proteins of SARS-COV-2 virus

Intervention type: DIAGNOSTIC_TEST
Intervention: IgG neutralising antibody titers to S1 and S2 proteins of SARS-COV-2 virus
Description: IgG neutralising antibody titers to S1 and S2 proteins of SARS-COV-2 virus
Study: NCT06339567

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Thrombotic profile
Description: several thrombotic biological marker will be dosed in blood. (C protein, S protein, CRP us, Factor VIII, TFPI , nAPCsr, SHBG, nTMsr)
Study: NCT05371145

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Carnosine
Description: Determine whether carnosine supplementation (2 g/day) for 3 months in peripheral arterial disease patients improves 6MWT ability.